
Sign up to save your podcasts
Or
Roy Herbst discusses the Zodiac trial, a phase 3 study assessing the efficacy of vandetanib for treating advanced non-small-cell lung cancer.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
5
11 ratings
Roy Herbst discusses the Zodiac trial, a phase 3 study assessing the efficacy of vandetanib for treating advanced non-small-cell lung cancer.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
756 Listeners
811 Listeners
131 Listeners
325 Listeners
38 Listeners
493 Listeners
58 Listeners
90 Listeners
1,095 Listeners
43 Listeners
318 Listeners
185 Listeners
794 Listeners
23 Listeners
0 Listeners
0 Listeners
2 Listeners
0 Listeners
2 Listeners
1 Listeners
0 Listeners
0 Listeners
1 Listeners
0 Listeners
0 Listeners
1 Listeners
0 Listeners
0 Listeners
0 Listeners
0 Listeners
0 Listeners
169 Listeners
0 Listeners